Kyverna Therapeutics, Inc. (KYTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
5980 Horton Street
Emeryville, CA 94608
United States of America (the)
Phone
(510) 925-2492
Website
Sector
Healthcare
Industry
Biotechnology
Employees
149
First IPO Date
February 09, 2024
| Name | Title | Pay | Year Born |
| Warner Biddle | Chief Executive Officer & Director | 1.27M | 1967 |
| Christi L. Shaw | Executive Chairperson | 144,940 | 1967 |
| Gregory Martini | Chief Financial Officer | 563,511 | 1989 |
| Marc Grasso | Strategic Advisor | 563,511 | 1973 |
| Mayo Pujols | Chief Technology Officer | 591,360 | 1970 |
| Naji Gehchan | Chief Medical & Development Officer | 975,073 | 1982 |
| Ritesh Srivastava | Chief Legal & Compliance Officer | 0 | N/A |
| Cara Bauer | Chief Human Resources Officer | 0 | N/A |
| Jessica Serra | Head of Investor Relations | 0 | N/A |
| Tracy Rossin | Senior Vice President of Corporate Affairs | 0 | 1977 |
| Tom Van Blarcom | Senior Vice President & Head of Research | 0 | N/A |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.